Pyrazinamide (PZA), an antituberculosis drug, may cause hypersensitivity reactions. Here, we report a case of anaphylaxis secondary to a PZA administration for tuberculosis pleuritis. To the best of our knowledge, this is the first reported case of strongly possible IgE-mediated, PZA-induced anaphylaxis proved by skin prick test and oral provocation/desensitization.

Keywords:
Anaphylaxis, Pyrazinamide, Prick test, Desensitization
1.
Aouam K, Chaabane A, Loussaïef C, Ben Romdhane F, Boughattas NA, Chakroun M: Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management. Med Mal Infect 2007;37:253–261.
2.
Blumberg HM, Burman WJ, Chaisson RE, et al: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–662.
3.
Olivier C, Radal M, Mazaud S, Jonville-Béra AP, Martel C, Autret E: Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide. Arch Pediatr 1998;5:289–290.
4.
Radal M, Jonville-Bera AP, Van-Egroo C, Carré P, Lemarié E, Autret E: Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide. Rev Mal Respir 1998;15:305–306.
5.
Brockow K, Romano A, Blanca M, Ring J, Picher W, Demoly P: General considerations for skin test procedure in the diagnosis of drug hypersensitivity. Allergy 2002;57:45–51.
6.
Rodrigues Carvalho S, Silva I, Leiria-Pinto P, Rosado-Pinto J: Rapid oral tolerance induction to isoniazid and pyrazinamide and controlled administration of ethambutol: clinical case. Allergol Immunopathol 2009;37:336–338.
7.
Fekih L, Fenniche S, Boussoffara L, Hassene H, Abdelghaffar H, Belhabib D, Megdiche Mohamed L: Hypersensitivity reactions to antituberculous therapy. Rev Mal Respir 2010;27:673–678.
8.
Ribi C, Hausher C: Adverse reactions to pyrazinamide. Allergy 2002;57:964–965.
9.
Schnyder B: Approach to the patient with drug allergy. Immunol Allergy Clin N Am 2009;29:405–418.
10.
Florvaag E, Johansson SGO: The pholcodine story. Immunol Allergy Clin N Am 2009;29:419–427.
11.
Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et al: European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity. General considerations on rapid desensitization for drug hypersensitivity – a consensus statement. Allergy 2010;65:1357–1366.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.